Primary Site >> Pancreatic Cancer
Gene >> CSF2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Purification of a colony-stimulating factor from cultured pancreatic carcinoma cells. PMID: 312800 |
Ref: Antibody to purified human colony-stimulating factor: use in the identification and isolation of granulocyte macrophage progenitor cells. PMID: 7008869 |
Ref: Induced release and metabolism of arachidonic acid from myeloid cells by purified colony-stimulating factor. PMID: 6813342 |
Ref: Further evidence supporting an in vivo role for colony-stimulating factor. PMID: 6334613 |
Ref: [Metastases to the nervous system]. PMID: 4058615 |
Ref: Pancreatic carcinoma associated with marked eosinophilia: a case report. PMID: 3500871 |
Ref: Proliferation of gastrointestinal carcinoma cells by T lymphocyte factors interleukin-3 and granulocyte-macrophage colony-stimulating factor. PMID: 1955751 |
Ref: Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma. PMID: 8620409 |
Ref: Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells. PMID: 9286413 |
Ref: Impaired in vivo tumor growth of human pancreatic carcinoma cells retrovirally transduced with GM-CSF gene. PMID: 9568072 Ref: Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. PMID: 9612602 Ref: A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. PMID: 9741433 |
Ref: Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation. PMID: 10214865 Ref: Immunotherapy of cancer. PMID: 10667204 |
Ref: GM-CSF gene therapy using adenoviral vector in hamster pancreatic cancer. PMID: 10982631 Ref: Generation and functional characterisation of dendritic cells from patients with pancreatic carcinoma with special regard to clinical applicability. PMID: 11129325 |
Ref: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. PMID: 11134207 Ref: Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. PMID: 11169257 Ref: Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. PMID: 11291084 Ref: Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma. PMID: 11531937 |
Ref: Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters. PMID: 12104046 Ref: Oncolytic herpes simplex virus vectors for cancer virotherapy. PMID: 12522436 |
Ref: Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. PMID: 15289501 Ref: Prevention and reversal of tumor cell-induced monocyte deactivation by cytokines, purified protein derivative (PPD), and anti-IL-10 antibody. PMID: 15327279 |
Ref: The potential of oncolytic virus therapy for pancreatic cancer. PMID: 15818382 Ref: Hematopoietic cytokines in the sera of patients with pancreatic cancer. PMID: 15843207 |
Ref: Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. PMID: 17060934 |
Ref: Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. PMID: 18039393 |
Ref: Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. PMID: 18316569 Ref: Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. PMID: 18383873 Ref: Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. PMID: 18941250 |
Ref: Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients. PMID: 19798410 Ref: Effect of insulin on functional status of cord blood-derived dendritic cells and on dendritic cell-induced CTL cytotoxicity against pancreatic cancer cell lines. PMID: 19822498 |
Ref: Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects. PMID: 20047504 Ref: Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines. PMID: 20734041 Ref: The therapeutic value of monoclonal antibodies directed against immunogenic tumor glycoproteins. PMID: 21060731 |
Ref: A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. PMID: 21217520 |
Ref: Novel agents in early phase clinical studies on refractory pancreatic cancer. PMID: 22406592 Ref: Silencing the killers: paracrine immune suppression in pancreatic cancer. PMID: 22698396 Ref: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. PMID: 22698406 Ref: Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. PMID: 22698407 Ref: Pancreatic cancer: The role of GM-CSF in pancreatic cancer unveiled. PMID: 22733349 Ref: Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer. PMID: 22865301 |
Ref: Impact of cytokines on diffuse splenic 18F-fluorodeoxyglucose uptake during positron emission tomography/computed tomography. PMID: 23076270 Ref: Block/homo polyplex micelle-based GM-CSF gene therapy via intraperitoneal administration elicits antitumor immunity against peritoneal dissemination and exhibits safety potentials in mice and cynomolgus monkeys. PMID: 23422727 Ref: Inflammatory networks and immune surveillance of pancreatic carcinoma. PMID: 23422836 Ref: Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. PMID: 23514705 Ref: Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. PMID: 23817426 Ref: Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. PMID: 23924790 Ref: Preclinical evaluation of herpes simplex virus armed with granulocyte-macrophage colony-stimulating factor in pancreatic carcinoma. PMID: 23964149 Ref: Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine. PMID: 24046118 Ref: A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma. PMID: 24829746 |
Ref: The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. PMID: 24292263 Ref: Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. PMID: 24919654 Ref: Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. PMID: 24942756 Ref: Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. PMID: 24947606 Ref: Novel pancreatic cancer vaccines could unleash the army within. PMID: 24955709 Ref: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. PMID: 25008236 Ref: Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells. PMID: 25128650 |
Ref: Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. PMID: 24832153 Ref: GMCSF-armed vaccinia virus induces an antitumor immune response. PMID: 25042001 Ref: Association between Variants in Atopy-Related Immunologic Candidate Genes and Pancreatic Cancer Risk. PMID: 25945796 Ref: Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer. PMID: 25952647 Ref: TGF-beta blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner. PMID: 26515728 |
Ref: Primary analysis for clinical efficacy of immunotherapy in patients with pancreatic cancer. PMID: 26565954 Ref: Surveying the serologic proteome in a tissue-specific kras(G12D) knockin mouse model of pancreatic cancer. PMID: 26572242 Ref: Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. PMID: 26719429 Ref: Increasing the Inflammatory Competence of Macrophages with IL-6 or with Combination of IL-4 and LPS Restrains the Invasiveness of Pancreatic Cancer Cells. PMID: 26722359 Ref: Circulating myeloid-derived suppressor cells in patients with pancreatic cancer. PMID: 26818550 Ref: Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. PMID: 26842750 Ref: Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. PMID: 26931369 Ref: GM-CSF Mediates Mesenchymal-Epithelial Cross-talk in Pancreatic Cancer. PMID: 27184426 Ref: GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro. PMID: 28090321 |
Ref: Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. PMID: 27974697 Ref: Granulocyte Colony-stimulating Factor Producing Anaplastic Carcinoma of the Pancreas: Case Report and Review of the Literature. PMID: 28011495 Ref: Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. PMID: 28254412 Ref: Abscopal effect of metastatic pancreatic cancer after local radiotherapy and granulocyte-macrophage colony-stimulating factor therapy. PMID: 28267380 Ref: The role of stromal cancer-associated fibroblasts in pancreatic cancer. PMID: 28351381 Ref: The pancreatic tumor microenvironment drives changes in miRNA expression that promote cytokine production and inhibit migration by the tumor associated stroma. PMID: 28903323 Ref: Apolipoprotein A-I mimetic peptide 4F suppresses tumor-associated macrophages and pancreatic cancer progression. PMID: 29245934 |
Ref: Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naive pancreatic cancer patients. PMID: 29316343 Ref: Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. PMID: 30232221 |